ZURICH (Reuters) - Novartis has agreed with Ionis Pharmaceuticals Inc and its affiliate Akcea Therapeutics Inc to license two experimental cardiovascular treatments in a deal which Ionis said could eventually be worth more than $1 billion.
The treatments aim to reduce cardiovascular risk in patients with high levels of lipoproteins. The therapies called AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx have the potential to lower lipoproteins Lp(a) and ApoCIII by up to 90 percent, Novartis said in a statement on Friday.
Ionis and Akcea are eligible to receive $225 million in near-term payments, including a $75 million up-front option payment and a $100 million equity investment in Ionis, Ionis said in a separate statement.
The deal would be valued at "significantly over $1 billion" through license fees, milestone payments and royalties if both drugs are licensed and successfully commercialised, Ionis said.
Basel-based Novartis said it can exercise its options to license and commercialise the two products after they hit specified development milestones and before phase 3 trials for each programme begin.
Novartis would then be responsible for worldwide development and commercialisation of both assets.
Shares in Novartis fell 14.6 percent in 2016, a steeper drop than the broader European healthcare index.
(Reporting by Michael Shields and Joshua Franklin)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
